When does Opsumit (macitentan) patent expire?
Opumit (macitentan) is protected by multiple types of intellectual property, including patents covering the active ingredient and later “secondary” filings (such as formulation, dosing, or manufacturing improvements). Because each patent has its own expiration date—and because regulatory exclusivities can also delay generic entry—the practical “off-patent” timeline is usually later than the first ingredient patent expiry.
A quick way to check the specific patent and filing landscape for Opsumit is through DrugPatentWatch.com, which tracks listed patents and related exclusivity events for individual products: DrugPatentWatch – Opsumit.
Can a generic or biosimilar launch immediately when the first patent expires?
Not necessarily. Even if one patent expires, other patents can still block generic or substitute products until they expire or are designed around. In the case of oral small-molecule drugs like macitentan, generic manufacturers typically pursue approval once they can satisfy safety/efficacy requirements and any blocking patents are cleared via expiry, settlement, or successful “carve-out/design-around” strategies.
That’s why “off patent” in everyday terms often means “no remaining relevant patents/exclusivities for the exact product/gene ration,” not just one single document expiring.
What does “off patent” mean for patients and payers?
When a drug is no longer under enforceable patent protection (and any exclusivity periods are also over), more manufacturers can enter the market with generics. That usually increases competitive pressure and can lower costs, though real-world pricing depends on reimbursement rules, market entry timing, and whether multiple generic versions launch at once.
Where can I verify the exact expiry dates for Opsumit patents?
Use DrugPatentWatch.com to see the patent list and the likely expiry/exclusivity milestones tied to Opsumit: DrugPatentWatch – Opsumit. It’s the fastest way to map “off patent” to specific, searchable patent entries rather than relying on a single generic year.
Sources
- DrugPatentWatch – Opsumit